Apexigen

📍 San Carlos, United States👥 14 employees💰 Last funded Oct 2019
Biotechnology Research🌐 apexigen.com
Website LinkedIn
Apexigen is a clinical-stage biopharmaceutical company discovering and developing a new generation of antibody therapeutics for the treatment of cancer with an emphasis on new immuno-oncology products designed to harness the patient’s immune system to combat and eradicate cancer. Its lead immuno-oncology drug candidate, sotigalimab, is a potent immune-activating antibody against CD40 currently in Phase 2 clinical development.
5
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

5 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
United States
4
China
1
Investor activity2017–2019 · investors recorded per year
201712018220192
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Apexigen?
Apexigen has 5 investors on record on gritt.io.
When did Apexigen last raise funding?
The most recent investment in Apexigen recorded on gritt.io was in October 2019.
What industry is Apexigen in?
Apexigen operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Apexigen based?
Apexigen is headquartered in San Carlos, United States.